Summary
The current pandemic continues to inspire Life Sciences companies to adapt and innovate, including by engaging in mergers, acquisitions, financings, collaborations, and other transactions that may trigger review under the antitrust laws. To avoid any pitfalls, Life Sciences companies should be aware of certain types of transactions that require notification to the antitrust agencies under the HSR Act as well as how the agencies will analyze these transactions under the antitrust laws.
This webinar will also provide important updates on the antitrust agencies’ enforcement activities regarding competitor collaborations in light of the current pandemic and practical tips to help avoid antitrust risks.
Speakers
- /en/people/j/jin-paul
Paul S. Jin
Partner - /en/people/m/mercier-jacqueline
Jacqueline Mercier
Partner